Literature DB >> 16330446

Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.

Donald P Mc Lornan, Melanie J Percy, Amy V Jones, Nicholas C P Cross, Mary Frances Mc Mullin.   

Abstract

Chronic neutrophilic leukemia (CNL) is a rare disease and can cause considerable diagnostic difficulty. Although the V617F JAK2 mutation has been described by several groups to be associated with classical myeloproliferative disorders (MPD), this same mutation has been detected with a low incidence in atypical MPD, such as CNL. Here we report the presence of the V617F mutation in a CNL patient, who is unusual for having survived for more than 96 months, with little disease progression. It remains to be established what role this mutation, which gives cells a proliferative advantage, might play in the pathogenesis and prognosis of rare atypical MPD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330446

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

1.  Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors:  S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal:  Ir J Med Sci       Date:  2007-04-18       Impact factor: 1.568

2.  Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments.

Authors:  Anurima Majumder; Annet Kirabo; Kanchana Karrupiah; Shigeharu Tsuda; Jennifer Caldwell-Busby; Arturo J Cardounel; György M Keseru; Peter P Sayeski
Journal:  Biochemistry       Date:  2011-08-17       Impact factor: 3.162

Review 3.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 4.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 5.  Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jeffrey W Tyner; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

6.  Chronic Neutrophilic Leukemia with V617F JAK2 Mutation.

Authors:  Smeeta Gajendra; Ritu Gupta; Meenal Chandgothia; Lalit Kumar; Richa Gupta; Snehal Motilal Chavan
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-25       Impact factor: 0.900

7.  Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Authors:  E Kouroupi; J-J Kiladjian; C Dosquet; M-L Menot; N Bonnin; L Ades; W Vainchenker; C Chomienne; B Cassinat
Journal:  Blood Cancer J       Date:  2012-05-04       Impact factor: 11.037

Review 8.  JAK2 V617F: a single mutation in the myeloproliferative group of disorders.

Authors:  Donal McLornan; Melanie Percy; Mary Frances McMullin
Journal:  Ulster Med J       Date:  2006-05

9.  Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation.

Authors:  Shinsaku Imashuku; Naoko Kudo; Kagekatsu Kubo; Katsuyasu Saigo; Nanako Okuno; Kaoru Tohyama
Journal:  J Blood Med       Date:  2012-12-05

Review 10.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.